William Young - Vertex Pharmaceuticals Independent Director
| VRTX Stock | MXN 8,150 42.60 0.53% |
Director
Mr. William D. Young is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Young is a Senior Advisor with Blackstone Life Sciences . Mr. Young joined Clarus Ventures, a life sciences VC firm, in 2010. Prior to Clarus Ventures, Mr. Young served from 1999 until June 2009 as the Chairman and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company acquired by Laboratory Corporation of America in June 2009. From 1980 to 1999, Mr. Young was employed at Genentech, Inc. in positions of increasing responsibility, including as Chief Operating Officer from 1997 to 1999, where he was responsible for all product development, manufacturing and commercial functions. Prior to joining Genentech, Mr. Young was with Eli Lilly Co. for 14 years. Mr. Young currently serves as the Chairman of the Board of Directors of NanoString Technologies, Inc., and as a member of the Board of Directors of Theravance BioPharma Inc. Mr. Young retired from BioMarin Pharmaceutical Inc.s Board of Directors in November 2015 and as Biogens Chairman of the Board in June 2014. Mr. Young holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from Indiana University and an Honorary Doctorate in Engineering from Purdue University. Mr. Young was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology. since 2014.
| Age | 74 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
William Young Latest Insider Activity
Tracking and analyzing the buying and selling activities of William Young against Vertex Pharmaceuticals stock is an integral part of due diligence when investing in Vertex Pharmaceuticals. William Young insider activity provides valuable insight into whether Vertex Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
William Young over three months ago Acquisition by William Young of 54545 shares of Smart Sand subject to Rule 16b-3 | ||
William Young over six months ago Acquisition by William Young of 17666 shares of Smart Sand subject to Rule 16b-3 | ||
William Young over six months ago Disposition of 5970 shares by William Young of Smart Sand at 1.94 subject to Rule 16b-3 | ||
William Young over six months ago Disposition of 4608 shares by William Young of Smart Sand at 1.9 subject to Rule 16b-3 |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ronald Williams | The Boeing | 69 | |
| Susan Schwab | The Boeing | 64 | |
| Luis Hernandez | Promotora y Operadora | 52 | |
| Fernando Sahagun | Bolsa Mexicana de | N/A | |
| Michael Splinter | Taiwan Semiconductor Manufactur | 69 | |
| Carlos Kolteniuk | Promotora y Operadora | 55 | |
| Peter Bonfield | Taiwan Semiconductor Manufactur | 74 | |
| Alberto Martinez | Bolsa Mexicana de | 56 | |
| Clementina Moreno | Bolsa Mexicana de | N/A | |
| KokChoo Chen | Taiwan Semiconductor Manufactur | N/A | |
| Blanca Vega | Bolsa Mexicana de | N/A | |
| Lynn Good | The Boeing | 59 | |
| Robert Bradway | The Boeing | 56 | |
| Frantz Devos | Promotora y Operadora | 63 | |
| Stan Shih | Taiwan Semiconductor Manufactur | N/A | |
| Aida Ancira | Bolsa Mexicana de | N/A | |
| Ramiro Abuin | Promotora y Operadora | 41 | |
| Arthur Collins | The Boeing | 71 | |
| Claudio Laporte | Bolsa Mexicana de | 85 | |
| Alberto Rodriguez | Bolsa Mexicana de | N/A | |
| Luis Alvarez | Promotora y Operadora | 45 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | ||
| Michael Parini, Executive Vice President, Chief Legal and Administrative Officer | ||
| Alan Garber, Independent Director | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Ex Chairman | ||
| MD FASN, Pres CEO | ||
| Stuart BSc, Ex COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Diana McKenzie, Independent Director | ||
| Sangeeta Bhatia, Independent Director | ||
| Terrence Kearney, Independent Director | ||
| Nia Tatsis, Senior Vice President Chief Regulatory Officer | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Corporate Controller | ||
| David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | ||
| Amit Sachdev, Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO | ||
| Charles Wagner, Chief Financial Officer, Executive Vice President | ||
| Gerald Bruce, Executive Vice President Commercial Operations | ||
| Ourania Tatsis, Ex Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, VP Relations | ||
| Lloyd Carney, Independent Director | ||
| Yuchun Lee, Independent Director | ||
| Stuart Arbuckle, Executive Vice President Chief Commercial Officer | ||
| Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | ||
| Jeffrey Leiden, Chairman of the Board, President, Chief Executive Officer |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 1.41 T | |||
| Shares Outstanding | 257.09 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 96.96 % | |||
| Price To Earning | 17.50 X | |||
| Price To Book | 6.07 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.